Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma

Affiliations

¹ The Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² The Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Editorial

Arlene O Siefker-Radtke et al. J Clin Oncol. 2023.

. 2023 Sep 1;41(25):4084-4086.

doi: 10.1200/JCO.23.00987. Epub 2023 Jul 25.

¹ The Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² The Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Comment on

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. O'Donnell PH, et al. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369081 Free PMC article. Clinical Trial.